<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83127">
  <stage>Registered</stage>
  <submitdate>3/09/2008</submitdate>
  <approvaldate>30/09/2008</approvaldate>
  <actrnumber>ACTRN12608000502336</actrnumber>
  <trial_identification>
    <studytitle>Effects of inhaled magnesium on pulmonary function and walking distance of patients with stable chronic obstructive pulmonary disease (COPD).</studytitle>
    <scientifictitle>Effects of inhaled magnesium on pulmonary function and walking distance of patients with stable chronic obstructive pulmonary disease (COPD).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients are going to be evaluated in two occasions within a crossover design
First treatment day:
#Inhalation of 300 mg of magnesium sulphate for 10 minutes.
# A 10 minute rest period
# Spirometry test
# Inhalation of 2,5 mg of salbutamol for 10 minutes after the spirometry.
# A second spirometry 10 minutes after the end of the inhalation of salbutamol
# A six minute walk test 10 minutes after the end of the last inhalation. 
All treatments are going to be administered only one time. A 48 hours wash-out period is going to respected between the first and second treatment days.</interventions>
    <comparator>The same patients are going to receive a treatment with placebo in a second occasion. 
All patients are going to be evaluated in two occasions within a crossover design. Second treatment day:
#Inhalation of 5m of saline for 10 minutes.
# A 10 minute rest period
# Spirometry test
# Inhalation of 2,5 mg of salbutamol for 10 minutes after the spirometry.
# A second spirometry 10 minutes after the end of the inhalation of salbutamol
# A six minute walk test 10 minutes after the end of the last inhalation. 
All treatments are going to be administered only one time.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in forced expiratory volume at the first second (FEV1)</outcome>
      <timepoint>Baseline and ten minutes after inhalation of magnesium or placebo</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Walking distance in a 6 minute walking test</outcome>
      <timepoint>Ten minutes after the end of the last inhalation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with chronic obstructive pulmonary disase of any severity.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active smokers; patients with any cardiac condition, diabetes mellitus or kidney failure.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Simple randomization. The volunteers  are going to choose one among several opaque envelopes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>5/09/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>José Antônio Baddini Martinez MD, PhD</primarysponsorname>
    <primarysponsoraddress>Avenida Bandeirantes 3900, Ribeirão Preto, São Paulo</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Hospital das Clinicas de Ribeirao Preto</fundingname>
      <fundingaddress>Avenida Bandeirantes 3900, Ribeirao Preto, Sao Paulo</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Hospital das Clinicas de Ribeirao Preto</sponsorname>
      <sponsoraddress>Avenida Bandeirantes 3900, Ribeirao Preto, Sao Paulo</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Camila Benedet</othercollaboratorname>
      <othercollaboratoraddress>Avenida Bandeirantes 3900, Ribeirao Preto, Sao Paulo</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Twenty four COPD patients in stable clinical conditions, for at least one month, are going to be enrolled in the study. The tests are going to be performed in two ocasions, at least two days apart. All the patients will go to the pulmonary function laboratory without use of any bronchodilator for at least 12 hours. They are going to perform a simple spirometry at baseline and minutes after an inhalation with 300 mg of magnesium or placebo. After a second spirometry, the patients are going to receive an additional inhalation with salbutamol 2.5 mg. The patients are going to perform a third spirometry minutes after the last inhalation. Finally they are going to perform a six minute walk test in both ocasions.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica do Hospital das Clinicas de Ribeirao Preto</ethicname>
      <ethicaddress>Avenida Bandeirantes 3900, Ribeirao Preto, Sao Paulo</ethicaddress>
      <ethicapprovaldate>4/03/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>José Antônio Baddini Martinez</name>
      <address>Avenida Bandeirantes 3900, Ribeirão Preto, São Paulo</address>
      <phone>16-36022531</phone>
      <fax>16-36336695</fax>
      <email>jabmarti@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>José Antônio Baddini Martinez MD, PhD</name>
      <address>Avenida Bandeirantes 3900, Ribeirão Preto, São Paulo</address>
      <phone>16-36022531</phone>
      <fax>16-36336695</fax>
      <email>jabmarti@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>José Antônio Baddini Martinez</name>
      <address>Avenida Bandeirantes 3900, Ribeirão Preto, São Paulo</address>
      <phone>16-36022531</phone>
      <fax>16-36336695</fax>
      <email>jabmarti@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>